{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:33:43Z","timestamp":1794569623997,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.biomaterials.2024.122951","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:09:51Z","timestamp":1730916591000},"page":"122951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Engineered VNP20009 expressing IL-15&amp;15R\u03b1 augments anti-tumor immunity for bladder cancer treatment"],"prefix":"10.1016","volume":"315","author":[{"given":"Bo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-1039","authenticated-orcid":false,"given":"Zhuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc3858","article-title":"Modelling bladder cancer in mice: opportunities and challenges","volume":"15","author":"Kobayashi","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122951_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"40","key":"10.1016\/j.biomaterials.2024.122951_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201901932","article-title":"Fluorinated polyethylenimine to enable transmucosal delivery of photosensitizer\u2010conjugated catalase for photodynamic therapy of orthotopic bladder tumors postintravesical instillation","volume":"29","author":"Li","year":"2019","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette\u2013Gu\u00e9rin\u2010unresponsive non\u2010muscle\u2010invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int. J. Urol."},{"issue":"19","key":"10.1016\/j.biomaterials.2024.122951_bib6","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122951_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122951_bib9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non\u2010muscle\u2010invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122951_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biomaterials.2024.122951_bib12","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","article-title":"BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?","volume":"39","author":"Lebacle","year":"2021","journal-title":"World J. Urol."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4161\/hv.5.2.7210","article-title":"BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy","volume":"5","author":"Liu","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"7\u20138","key":"10.1016\/j.biomaterials.2024.122951_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.biomaterials.2024.122951_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122951_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1074-7613(00)80246-0","article-title":"IL-15: a pleiotropic cytokine with diverse receptor\/signaling pathways whose expression is controlled at multiple levels","volume":"4","author":"Tagaya","year":"1996","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122951_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122951_bib20","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122951_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2017.02.028","article-title":"IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer","volume":"145","author":"Felices","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122951_bib23","article-title":"ALT-803 in the treatment of non-muscle-invasive bladder cancer: preclinical and clinical evidence and translational potential","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122951_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.biomaterials.2024.122951_bib25","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1073\/pnas.1405514111","article-title":"IL-15. IL-15R\u03b1 complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells","volume":"111","author":"Tamzalit","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122951_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20041389","article-title":"Coordinate expression and trans presentation of interleukin (IL)-15R\u03b1 and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis","volume":"200","author":"Burkett","year":"2004","journal-title":"J. Exp. Med."},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122951_bib27","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","article-title":"Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial","volume":"28","author":"Miller","year":"2022","journal-title":"Nat. Med."},{"issue":"5S","key":"10.1016\/j.biomaterials.2024.122951_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001008640.01272.9d.03","article-title":"MP16-03 N-803 plus BCG complete response rate in NMIBC CIS subjects: BCG refractory, pelapsed, checkpoint failure, and chemotherapy failure; updated results (QUILT 3.032)","volume":"211","author":"Soon-Shiong","year":"2024","journal-title":"J. Urol."},{"issue":"11\u201312","key":"10.1016\/j.biomaterials.2024.122951_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3727\/096504001108747512","article-title":"Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models","volume":"12","author":"Luo","year":"2001","journal-title":"Oncol. Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122951_bib31","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1086\/315497","article-title":"Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimuvium","volume":"181","author":"Clairmont","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ijc.22688","article-title":"Tumor\u2010targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low\u2010dose metronomic regimens in a murine melanoma model","volume":"121","author":"Jia","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2002.20.1.142","article-title":"Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma","volume":"20","author":"Toso","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002371-200303000-00011","article-title":"Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma","volume":"26","author":"Heimann","year":"2003","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib35","article-title":"Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/cbt.7.1.5195","article-title":"therapy, Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic","volume":"7","author":"Yang","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biomaterials.2024.122951_bib37","article-title":"Flagella of tumor\u2010targeting bacteria trigger local hemorrhage to reprogram tumor\u2010associated macrophages for improved antitumor therapy","author":"Xu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2024.122951_bib38","doi-asserted-by":"crossref","first-page":"101070","DOI":"10.1016\/j.xcrm.2023.101070","article-title":"Targeted deprivation of methionine with engineered Salmonella leads to oncolysis and suppression of metastasis in broad types of animal tumor models","author":"Zhou","year":"2023","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.biomaterials.2024.122951_bib39","first-page":"960","article-title":"A heat\u2010inducible expression system for external control of gene expression in plastids","author":"Xu","year":"2023","journal-title":"Plant Biotechnol. J."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122951_bib40","first-page":"1312","article-title":"Construction and application of a new prokaryotic expression vector derivative of pBV220","volume":"24","author":"Zhu","year":"2008","journal-title":"Chin. J. Biotechol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3727\/096504001108747602","article-title":"Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector","volume":"12","author":"Zheng","year":"2001","journal-title":"Oncol. Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122951_bib42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2249.2001.01672.x","article-title":"IL-15-induced conversion of monocytes to mature dendritic cells","volume":"126","author":"Saikh","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.biomaterials.2024.122951_bib43","series-title":"Intravesical Instillation Therapy","first-page":"53","author":"Suh","year":"2019"},{"key":"10.1016\/j.biomaterials.2024.122951_bib44","series-title":"Epidemiology, Control, Evolution and Strain Variation in BCG","first-page":"155","author":"Abdallah","year":"2017"},{"key":"10.1016\/j.biomaterials.2024.122951_bib45","doi-asserted-by":"crossref","first-page":"107318","DOI":"10.1016\/j.intimp.2020.107318","article-title":"Biological Effects of IL-15 on Immune Cells and its Potential for the Treatment of Cancer","volume":"91","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biomaterials.2024.122951_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","article-title":"Immunobiology of the IL-15\/IL-15R\u03b1 Complex as an Antitumor and Antiviral Agent","volume":"38","author":"Guo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biomaterials.2024.122951_bib47","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15R\u03b1 immunotherapy maximizes IL-15 activity in vivo","volume":"9","author":"Stoklasek","year":"2006","journal-title":"J Immunol.177"},{"key":"10.1016\/j.biomaterials.2024.122951_bib48","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1073\/pnas.0600240103","article-title":"Converting IL-15 to a superagonist by binding to soluble IL-15R\u03b1","volume":"24","author":"Rubinstein","year":"2006","journal-title":"Proc. Natl. Acad. Sci.103"},{"key":"10.1016\/j.biomaterials.2024.122951_bib49","doi-asserted-by":"crossref","first-page":"1040669","DOI":"10.3389\/fimmu.2022.1040669","article-title":"ALT-803 in the Treatment of Non-muscle-invasive Bladder Cancer: Preclinical and Clinical Evidence and Translational Potential","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib50","doi-asserted-by":"crossref","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus calmette-gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biomaterials.2024.122951_bib51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.JU.0000557510.69076.c9","article-title":"LBA-18 Preliminary phase 2 clinical results of IL-15R\u03b1FC superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients demonstrates 82% CR of carcinoma in situ (CIS)","volume":"201","author":"Chamie","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.biomaterials.2024.122951_bib52","first-page":"5678702","article-title":"Strains, mechanism, and perspective, Salmonella\u2010based cancer therapy","volume":"1","author":"Wang","year":"2016","journal-title":"Int. J. Microbiol."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122951_bib53","doi-asserted-by":"crossref","first-page":"5678702","DOI":"10.1136\/jitc-2021-004325","article-title":"Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors","volume":"10","author":"Moreo","year":"2022","journal-title":"J. Immunother Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122951_bib54","article-title":"Engineered oncolytic bacteria for malignant solid tumor treatment Interdisciplinary","volume":"2","author":"Wang","year":"2024","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122951_bib55","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1086\/315497","article-title":"Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimuvium","volume":"181","author":"Clairmont","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122951_bib56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.trecan.2022.03.007","article-title":"Natural killer cells: unlocking new treatments for bladder cancer","volume":"8","author":"Ranti","year":"2022","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122951_bib57","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2024.122951_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2020.00275","article-title":"Unleashing Natural Killer Cells in the Tumor Microenvironment\u2013The Next Generation of Immunotherapy?","volume":"11","author":"Ben-Shmuel","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122951_bib59","first-page":"613","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122951_bib60","first-page":"10","article-title":"Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer","volume":"7","author":"Liakou","year":"2007","journal-title":"Cancer Immun."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122951_bib61","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224004861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224004861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T14:14:59Z","timestamp":1735049699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224004861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":61,"alternative-id":["S0142961224004861"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122951","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered VNP20009 expressing IL-15&15R\u03b1 augments anti-tumor immunity for bladder cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122951"}}